skip to content
Primary navigation
Feature image for 2021 Evaluation Reports

2021 Evaluation Reports

62J evaluation reports submitted by the Department of Commerce to the Legislature in 2021

  • Evaluation of HF1041-1E: Would require regulated health plans in Minnesota to provide coverage for services related to ectodermal dysplasia. 
  • Evaluation of HF58-2E: Would require health plans and PBMs to file their prescription drug formularies and to use a realtime prescription drug benefit tool.
  • Evaluation of HF447-1E and HF2414: Both bills would require regulated health plans in Minnesota to provide additional coverage for breast cancer screening follow-up services. 
  • Evaluation of HF633-1E: Would requires that individual and small group health carriers provide a flat-dollar, pre-deductible copayment for all tiers of drugs in at least 25 percent of the plans offered in each geographic rating area in which they operate. 
  • Evaluation of HF785-1E: Would require health plans to provide coverage for acupuncture services specifically related to treatment of ongoing pain. 
  • Evaluation of SF97: Would require regulated health plans in Minnesota to provide certain coverage for lymphedema treatment. 
back to top